Navigation Links
Cardium to Present at the Rodman & Renshaw Annual Healthcare Investment Conference
Date:9/1/2011

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that Christopher J. Reinhard, Chairman and Chief Executive Officer, will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Tuesday, September 13, 2011, at 2:25 p.m. Eastern Time.  The conference is being held September 11-13 at The Waldorf-Astoria in New York City.  An audio webcast of the Company's presentation will be available live and by replay and can be accessed at http://www.wsw.com/webcast/rrshq20/cxm or the Investors section of Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar.  The investor presentation slides are available and can be viewed at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations.  Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium healthy lifestyle product platform.  The Company's lead product candidates include Excellagen™ topical gel for wound care management, and Generx® DNA-based angiogenic biologic for patients with coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Copyright 2011 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™ and Nutra-Apps™ are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Provides Update on Exchange Listing and Related Business Matters
2. Cardium to Present at Southern California Investor Conference
3. Cardium Announces Receipt of $1.1 Million in Funds from Philips Acquisition of Innercool Therapies
4. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
5. Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans
6. Cardium Reports on Transdel Transaction
7. Cardium Announces Market Introduction of New Alena™ Clinical Strength Carb Blocker to Expand the MedPodium Healthy Lifestyle Product Line
8. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
9. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
10. Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term Milestones
11. Cardium to Present at OneMedForum San Francisco 2011 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer ... prospects of the market globally. The stakeholders of ... the manufacture and commercialization of various mass spectrometer ... planning to enter this market. This report comprises ...
(Date:2/21/2017)... -- Luminex Corporation (NASDAQ: LMNX ) (the "Company") today ... of a quarterly cash dividend to its shareholders, the first ... payable on April 14, 2017 to shareholders of record as ... The board of directors intends for the Company ... holders of its common stock, representing a planned annual dividend ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... ... As recently as 2015, rhinoplasty was one of the Top 5 cosmetic ... patients want to make a change in the appearance of their nose while others ... team at usrhinoplasty.org is expanding its article database to better inform its ...
(Date:2/21/2017)... ... 2017 , ... American Veterinarian™, the premier multimedia provider of ... first bi-monthly issue of 2017 in February. The inaugural issue will offer expert ... , In making the announcement, American Veterinarian™ Publisher Chris Hennessy said, “We ...
(Date:2/21/2017)... San Francisco, California (PRWEB) , ... February 21, ... ... in the world with over 50,000 participants. The connected care demonstration spanned ... Office of the National Coordinator, roughly 30% of providers have no Health Information ...
(Date:2/21/2017)... ... February 21, 2017 , ... Along with Valentine’s Day, February marks ... small changes that can lead to a lifetime of heart health. In addition, ... emergency. , The Athletic Trainers’ Society of New Jersey (ATSNJ) is urging ...
(Date:2/20/2017)... ... 20, 2017 , ... Daily Body Restore, "DBR" a company ... “good” bacteria in the body, announced its Daily Body Restore® supplement is now ... Body Restore® is made with a unique combination of digestive enzymes and probiotics ...
Breaking Medicine News(10 mins):